Spyre Therapeutics reports SPY072 fails psoriatic arthritis trial as Ideaya halts eye cancer study

Spyre Therapeutics announced that its long‑acting anti‑TL1A candidate, SPY072, did not meet the primary endpoints in a psoriatic arthritis trial.

The result adds to recent setbacks for Spyre in other disease programs, highlighting ongoing development challenges.

Ideaya Therapeutics disclosed that it is ending its eye cancer trial, bringing another program to a close.

United Therapeutics was also referenced in the briefing, though no specific outcomes were detailed.

Together, these updates illustrate the difficulty of advancing novel immunomodulatory therapies in competitive markets.